| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Alleviating retroperitoneal pain with celiac plexus radiosurgery
|
Moore-Palhares, Daniel
|
|
|
25 |
8 |
p. 952-953
|
artikel
|
| 2 |
A manifesto for improving cancer detection: four key considerations when implementing innovations across the interface of primary and secondary care
|
Dowrick, Anna
|
|
|
25 |
8 |
p. e388-e395
|
artikel
|
| 3 |
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
|
Moreau, Philippe
|
|
|
25 |
8 |
p. 1003-1014
|
artikel
|
| 4 |
Call for stricter tobacco control laws in Ghana
|
Das, Manjulika
|
|
|
25 |
8 |
p. e338
|
artikel
|
| 5 |
Cancer and premature mortality—pushing the frontiers of cancer care
|
Olagunju, Andrew Toyin
|
|
|
25 |
8 |
p. 946-947
|
artikel
|
| 6 |
Cancer priorities set out in manifestos as organisations warn of worsening standards
|
Wilkinson, Emma
|
|
|
25 |
8 |
p. 957
|
artikel
|
| 7 |
Carcinogenicity of talc and acrylonitrile
|
Stayner, Leslie T
|
|
|
25 |
8 |
p. 962-963
|
artikel
|
| 8 |
Celiac plexus radiosurgery for pain management in advanced cancer: a multicentre, single-arm, phase 2 trial
|
Lawrence, Yaacov R
|
|
|
25 |
8 |
p. 1070-1079
|
artikel
|
| 9 |
Challenges and prospects for cancer treatment in prison settings
|
Hong, Hujian
|
|
|
25 |
8 |
p. e332
|
artikel
|
| 10 |
Challenges and prospects for cancer treatment in prison settings
|
Zhang, Feng
|
|
|
25 |
8 |
p. e333
|
artikel
|
| 11 |
Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis
|
Jenei, Kristina
|
|
|
25 |
8 |
p. 979-988
|
artikel
|
| 12 |
Closing the research gaps in obstetric health for survivors of cancer
|
Bajpai, Ranjeet
|
|
|
25 |
8 |
p. 953-955
|
artikel
|
| 13 |
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
|
Lin, Yi
|
|
|
25 |
8 |
p. e374-e387
|
artikel
|
| 14 |
Correction to Lancet Oncol 2024; 25: e374–87
|
|
|
|
25 |
8 |
p. e336
|
artikel
|
| 15 |
Correction to Lancet Oncol 2024; 25: e250–59
|
|
|
|
25 |
8 |
p. e336
|
artikel
|
| 16 |
Daratumumab maintenance in patients with myeloma
|
Beksac, Meral
|
|
|
25 |
8 |
p. 947-948
|
artikel
|
| 17 |
Dose selection of novel anticancer drugs: exposing the gap between selected and required doses
|
Hoog, Catharina J P Op ‘t
|
|
|
25 |
8 |
p. e340-e351
|
artikel
|
| 18 |
ESMO Gastrointestinal Cancers Congress 2024
|
Gourd, Katherine
|
|
|
25 |
8 |
p. 961
|
artikel
|
| 19 |
Evaluating the KEYNOTE-057 trial's findings: addressing demographic, methodological, and economic considerations
|
Wang, Shen
|
|
|
25 |
8 |
p. e335
|
artikel
|
| 20 |
Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial
|
Tendler, Salomon
|
|
|
25 |
8 |
p. 1015-1024
|
artikel
|
| 21 |
ImmunoPET in high-grade neuroendocrine tumours
|
Giammarile, Francesco
|
|
|
25 |
8 |
p. 949-950
|
artikel
|
| 22 |
Impact of pharmacy benefit managers on cancer health care
|
Venkatesan, Priya
|
|
|
25 |
8 |
p. e339
|
artikel
|
| 23 |
Incorporating whole-genome sequencing into cancer care
|
The Lancet Oncology,
|
|
|
25 |
8 |
p. 945
|
artikel
|
| 24 |
Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: an observational cohort study
|
Bertsimas, Dimitris
|
|
|
25 |
8 |
p. 1025-1037
|
artikel
|
| 25 |
Leaked documents suggest Philip Morris International's link to research activities
|
Burki, Talha
|
|
|
25 |
8 |
p. 964
|
artikel
|
| 26 |
Lifestyle factors driving cancer cases and mortality in the USA
|
Gruber, Karl
|
|
|
25 |
8 |
p. e337
|
artikel
|
| 27 |
Molecular diagnosis and site-specific therapy in cancer of unknown primary: an important milestone
|
Greco, F Anthony
|
|
|
25 |
8 |
p. 955-956
|
artikel
|
| 28 |
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study
|
Wan, Guihong
|
|
|
25 |
8 |
p. 1053-1069
|
artikel
|
| 29 |
New report from STRONG-AYA on addressing needs of adolescents and young adults with cancer in Europe
|
Das, Manjulika
|
|
|
25 |
8 |
p. 960
|
artikel
|
| 30 |
New Zealand expands cancer treatment with funding boost
|
Adepoju, Paul
|
|
|
25 |
8 |
p. 958
|
artikel
|
| 31 |
NHS cancer services and systems—ten pressure points a UK cancer control plan needs to address
|
Aggarwal, Ajay
|
|
|
25 |
8 |
p. e363-e373
|
artikel
|
| 32 |
Nigeria mandates reporting of all cancer diagnoses
|
Adepoju, Paul
|
|
|
25 |
8 |
p. 959
|
artikel
|
| 33 |
Perioperative immunotherapy in renal cell carcinoma
|
Borchiellini, Delphine
|
|
|
25 |
8 |
p. 950-951
|
artikel
|
| 34 |
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study
|
Allaf, Mohamad E
|
|
|
25 |
8 |
p. 1038-1052
|
artikel
|
| 35 |
Premature mortality trends in 183 countries by cancer type, sex, WHO region, and World Bank income level in 2000–19: a retrospective, cross-sectional, population-based study
|
Murthy, Shilpa S
|
|
|
25 |
8 |
p. 969-978
|
artikel
|
| 36 |
Primary cardiac angiosarcoma presenting as restrictive cardiomyopathy
|
Peterson, Joshua M
|
|
|
25 |
8 |
p. e396
|
artikel
|
| 37 |
Radiotherapy, immunity, and immune checkpoint inhibitors
|
Lynch, Connor
|
|
|
25 |
8 |
p. e352-e362
|
artikel
|
| 38 |
Risks of adverse obstetric outcomes among female survivors of adolescent and young adult cancer in England (TYACSS): a population-based, retrospective cohort study
|
Sunguc, Ceren
|
|
|
25 |
8 |
p. 1080-1091
|
artikel
|
| 39 |
Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial
|
Liu, Xin
|
|
|
25 |
8 |
p. 1092-1102
|
artikel
|
| 40 |
Sotorasib versus docetaxel: evidence supporting CodeBreaK 200
|
Paz-Ares, Luis
|
|
|
25 |
8 |
p. e334
|
artikel
|
| 41 |
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
|
Wu, Yi-Long
|
|
|
25 |
8 |
p. 989-1002
|
artikel
|
| 42 |
Together and apart: experiences of childhood brain tumour
|
Young, Kate
|
|
|
25 |
8 |
p. 965-966
|
artikel
|
| 43 |
Two-physician certification in end-of-life decision making
|
Sneider, Abigail P
|
|
|
25 |
8 |
p. 966-968
|
artikel
|
Tijdschrift beschrijving